IO Biotech, Inc. (IOBT) Dividend History

Company News

• IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

  IO Biotech, a clinical-stage biopharmaceutical company, presented new data at the AACR 2025 Annual Meeting, showcasing the dual mechanism and immune activation of its cancer vaccines IO102-IO103 and IO170.

  GlobeNewswire Inc.
• IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

  IO Biotech presented new preclinical data on its TGF-β-directed peptide vaccine, IO170, which showed reduced tumor growth in cancer models without causing systemic toxicity. The findings support the continued development of this immune-modulatory vaccine as a novel approach for treating a wide range of cancers.

  GlobeNewswire Inc.
• IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

  IO Biotech's off-the-shelf cancer vaccine IO102-IO103, in combination with Keytruda, showed promising activity and durability in a Phase 2 study for first-line treatment of metastatic lung cancer patients. The data also included positive pre-clinical results for IO Biotech's second vaccine candidate, IO112.

  GlobeNewswire Inc.

  Featured Companies: MRK
• IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

  IO Biotech's Phase 2 trial of its investigational cancer vaccine IO102-IO103 in combination with Merck's pembrolizumab showed promising results in treating advanced head and neck cancer, meeting the primary endpoint of overall response rate and demonstrating encouraging progression-free survival data.

  GlobeNewswire Inc.

  Featured Companies: MRK
• IO Biotech to Present at Jefferies Global Healthcare Conference

  NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced today that Mai-Britt Zocca, Ph.D., the company’s President and CEO, will be presenting, and both Dr. Zocca and Amy Sullivan, the company’s CFO, will be participating in one-on-one investor meetings at the Jefferies Global Healthcare Conference to be held June 4-6, 2024 in New York, NY.

  GlobeNewswire Inc.